PlainPharmaWatch

CMS Open Payments · Tool

Argenx US, Inc. vs Atricure, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Argenx US, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 327, versus 80 for the other company. Its single largest recorded recipient represents 16.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Argenx US, Inc.
HHI 327 · top recipient 16.2%
Ranked #1,433 of 1,838 companies by HHI
Atricure, Inc.
HHI 80 · top recipient 4.0%
Ranked #1,720 of 1,838 companies by HHI

Payment Overview

Company A

Argenx US, Inc.

Total Payments
$14.1M
% of Industry
0.1%
Transactions
23,579
Avg per Transaction
$599.09
Recipients
19,529
Avg per Recipient
$723.33
Payment Types
7
Top Payment Type
Consulting Fee
Company B

Atricure, Inc.

Total Payments
$13.7M
% of Industry
0.1%
Transactions
29,986
Avg per Transaction
$457.00
Recipients
28,870
Avg per Recipient
$474.67
Payment Types
5
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Argenx US, Inc. vs Atricure, Inc. - total reported payments in CMS Open Payments PY2024

Argenx US, Inc.$14.1MAtricure, Inc.$13.7M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Argenx US, Inc.

Consulting Fee $1.3M

37.7%

Compensation for Services Other Than Consulting $1.2M

34.1%

Food and Beverage $499.7K

14.2%

Travel and Lodging $392.3K

11.1%

Space Rental or Facility Fees $77.4K

2.2%

Grant $20.0K

0.6%

Atricure, Inc.

Consulting Fee $2.7M

55.3%

Food and Beverage $1.3M

27.3%

Travel and Lodging $802.4K

16.3%

Grant $56.5K

1.1%

Education $570.00

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Argenx US, Inc.

  1. 1

    PAMELA KLEIN

    $571,336.64 · 45 txns

  2. 2

    SAMIR MACWAN

    $103,462.25 · 137 txns

  3. 3

    JEFFERY ALLEN

    $81,652.82 · 64 txns

  4. 4

    BARRY VAUGHT

    $79,052.00 · 86 txns

  5. 5

    JOHN HEMPHILL

    $63,626.96 · 64 txns

Atricure, Inc.

  1. 1

    ARMIN KIANKHOOY

    $196,662.48 · 121 txns

  2. 2

    ERIC WILLIAM SCHNEEBERGER

    $145,410.13 · 124 txns

  3. 3

    KEVIN J. MAKATI

    $133,382.09 · 75 txns

  4. 4

    ANDREW JAMES SHERMAN

    $103,674.68 · 73 txns

  5. 5

    MARIO G GASPARRI

    $97,130.49 · 60 txns

Summary Comparison

Metric Argenx US, Inc. Atricure, Inc.
Total Payments $14.1M $13.7M
% of Industry Total 0.1% 0.1%
Transaction Count 23,579 29,986
Avg per Transaction $599.09 $457.00
Recipient Count 19,529 28,870
Avg per Recipient $723.33 $474.67
Payment Type Count 7 5
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.